Navigation Links
NxStage Medical Introduces New Products at 2013 American Society of Nephrology Meeting
Date:11/6/2013

LAWRENCE, Mass., Nov. 6, 2013 /PRNewswire/ -- NxStage Medical Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, is introducing  three new products at the American Society of Nephrology (ASN) Annual Kidney Week 2013 Meeting in Atlanta, GA November 5 – 10, 2013 at booth #1129. The new offerings include the NxStage System One™ S, Nx2me Connected Health™, and the NxStage Dosing Calculator.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

The NxStage System One S's higher dialysate flow rates allow for a wider range of flexible therapy options and a higher dose in the same time as it would take with the System One. The System One S allows nephrologists expanded possibilities to adjust the duration and frequency of patient prescriptions with greater flexibility than they have today.

Nx2me Connected Health leverages tablets, cloud computing and wireless communications. A key component of this solution is the Nx2me™ app, developed for the iPad® and used by patients at home. The app collects NxStage System One cycler data, as well as patient information such as blood pressure and weight. Patients can review, confirm, and transmit this data to their centers after each treatment. Dialysis center staff can access the transmitted data using the Nx2me™ Clinician Portal, gaining enhanced capabilities to review and follow treatment adherence and progress.

The new NxStage Dosing Calculator is an online tool that helps physicians develop prescriptions tailored to patients' clinical and lifestyle objectives. Using formulas from peer-reviewed publications, the Dosing Calculator quickly displays a wide range of therapy options to assist physicians in prescribing for a desired dose. This online tool is designed to reduce nephrologist time in calculating and assessing hundreds of possible prescription options to achieve clinical goals. The NxStage Dosing calculator, which is a free service, can be accessed directly at http://dosingcalculator.nxstage.com

"I'm very proud of our continued commitment to innovation and our ability to bring new products to market," said Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical, Inc. "We are really excited about the potential of these enhancements to improve both ease of use of our therapy and efficiency for providers, clinicians, and most importantly, our patients."

About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.

About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2013. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Kristen K. Sheppard, Esq.
Investor Relations
ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
2. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
3. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
4. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
5. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
6. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
7. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
8. NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
9. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
10. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
(Date:5/23/2016)... According to a new ... Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, Mechanical, ... Wound), Accessories (Lifting, Transfer) & by End User ... MarketsandMarkets, the patient handling equipment market is expected ... a CAGR of 10.5% during the forecast period ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... 25, 2016 , ... Today Omega Institute, a leading destination for yoga education ... training opportunities in the growing field of yoga therapy . Yoga therapy ... with specific health issues—including injuries, illnesses, and temporary or chronic health conditions. , “Yoga ...
(Date:5/25/2016)... ... 2016 , ... DKT International, one of the largest private ... to release their 2015 global impact data. In 2015, DKT served over 30 ... and 3.8 million unsafe abortions across 21 countries worldwide. , “We are ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... supporting the real time adjudication of medical service claims by Pharmacy Benefit Managers ... current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard professional ...
(Date:5/25/2016)... FRANCISCO, CA (PRWEB) , ... May 25, 2016 , ... ... School of Nursing and Health Professions. She will lead a team of more than ... Team. Baker will begin her role as dean in late August. , Baker comes ...
(Date:5/25/2016)... BEACH COUNTY, FLA (PRWEB) , ... May 25, 2016 , ... ... the latest technology to help turn back the hands of time of female aging. ... female aging and childbirth. Women with symptoms such as leakage, laxity, itchiness and ...
Breaking Medicine News(10 mins):